Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
ALLO-605 are allogeneic T-cells engineered to express a BCMA targeting chimeric antigen receptor (CAR), with TRAC and CD52 gene inactivation, which may lead to antitumor activity (Blood (2020) 136 (Supplement 1): 8).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|ALLO-605 + ALLO-647 + Cyclophosphamide + Fludarabine||ALLO-605 ALLO-647 Cyclophosphamide Fludarabine||0||1|